Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.

Inclusion criteria

• Age ≥ 16 years;
• Ability to express appropriate informed consent to treatment;
• Diagnosis of grade III meningioma (regardless of presence of residual) or diagnosis of recurrence of grade II meningioma (regardless of presence of residual) or first diagnosis of grade II meningioma with presence of residual;
• In case of recurrence, confirmation can be either histological or radiological;
• Not previous brain-level radiotherapy;
• Performance status: ECOG=0-2.

Exclusion criteria

• Refusal to radiation treatment (i.e., absence of signed informed consent);
• Other concomitant oncologic therapies
• Current pregnancy;
• Grade I meningiomas or Grade II meningiomas if operated on at first diagnosis with radical resection;
• Inability to perform MRI with MoC or PET.